You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Enabling self-reported outcomes for youth with developmental disabilities: The PediatricEvaluation of Disability Inventory- Patient Reported Outcome (PEDI-PRO)- Phase II
SBC: ABLELINK TECHNOLOGIES INC Topic: NICHDThe lack of patient reported outcome measures (PROMs) appropriate for youth with neurodevelopmental disabilities (DD) and related cognitive impairments including Down syndrome (DS) poses a significant problem for healthcare research and practice. Parents and other professionals do not identify the same needs as youth, and failure to engage youth with DD in healthcare evaluation compromises healthc ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Prevention of corneal transplant rejection using AAV-HLA-G combination therapy
SBC: Bedrock Therapeutics, Inc. Topic: NEIContact PD/PI: GILGER, BRIAN C Abstract Corneal blindness is a leading cause of global blindness, with allogeneic corneal transplantation (CT) being the most common form of tissue transplantation worldwide. Though approximately 180,000 CT surgeries are carried out each year, around 12.7 million are currently awaiting a donor cornea to undergo the operation. Still, CT surgery is accompanied by a hi ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis
SBC: Arrevus, Inc. Topic: NIAIDPROJECT SUMMARYSepsis is a life-threatening syndrome that involves a systemic inflammatory response that is initiated by an infection. There are an estimated 1.5 million of cases annually in the US with 250,000 resulting in death. The number of cases and associated deaths is expected to increase given the rising at-risk population of elderly individuals and the compounding challenge of antibiotic ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Examination of a novel potential therapy for autonomic dysreflexia
SBC: Dignify Therapeutics LLC Topic: NINDSPROJECT SUMMARY/ABSTRACT Autonomic dysreflexia (AD) is a potentially life-threatening hypertensive crisis that predominantly affects individuals with a spinal cord injury (SCI) above T6. AD can be triggered idiopathically or by distention or manipulation of pelvic visceral organs, especially the bladder and bowel, which can occur with catheterization and fecal evacuation procedures that are necess ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of Natural Product Inspired Adjuvants to Treat Tolerant Infections
SBC: Synoxa Sciences, Inc Topic: NIAIDProject Summary Natural products have served as a productive source of drugs over the past decades and have represented, or been the inspiration for, a majority of antimicrobial compounds that have entered the clinic. The goal of this proposal is to develop novel antibacterial adjuvants based on the marine natural product synoxazolidinone B to treat Gram-positive orthopedic joint infections. These ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Chemically controlling chromatin to treat Friedriech's Ataxia
SBC: Epigenos Bioscience, Inc. Topic: NCATSWe recently developed a technology that combines catalytically inactive dCas9 with bifunctional chemicals that link endogenous host cellular machinery to specific genes targeted with dCas9. We have demonstrated this technology can significantly increase gene expression at multiple endogenous mammalian genes in a chemically dependent manner. Here we propose to apply this technology to the mono-alle ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of Drug Delivery Technology for Stem Cell Based TMJ Regeneration
SBC: WNT SCIENTIFIC LLC Topic: NIDCR1 ABSTRACT2 The temporomandibular joint (TMJ) is a complex joint system critical for dental occlusion, mastication, 3 respiration and speech. The TMJ is comprised of a network of muscles, ligaments, and a4 fibrocartilaginous disc and condyle. Temporomandibular disorders (TMDs) afflict over 10 million5 Americans at an annual cost of ~$4 billion, per the NIDCR. Degenerative types of TMDs, including6 ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
CNS Gene Therapy for CLN2 Disease Using Parallel Multiple Routes of Administration
SBC: LEXEO Therapeutics LLC Topic: NINDSAbstract. In partnership with the Crystal laboratory, Weill Cornell, LEXEO is developing an adeno-associ- ated virus (AAV)-based gene therapy to treat the central nervous system (CNS) manifestations of CLN2 (Batten) disease, a fatal, childhood autosomal recessive neurodegenerative lysosomal storage disorder caused by mutations in the CLN2 gene, coding for a lysosomal enzyme, tripeptidyl peptidase ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Preventing outbreaks of foodborne pathogenic bacteria in edible sprouts via novel resistance-conferring seed treatments
SBC: Ascribe Bioscience Inc. Topic: NIAIDAbstract One of the most severe foodborne outbreaks in Europe, and the second-largest “Shiga toxin-producing” E. coli outbreak worldwide, was traced to E. coli O104: H4 in fresh fenugreek sprouts from a farm in Germany. It affected more than 4,075 individuals in 16 countries and included 908 cases complicated by hemolytic uremic syndrome (HUS) and 50 deaths. In the U.S., sprouts were implicate ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency
SBC: LEXEO Therapeutics LLC Topic: 999Abstract. LEXEO Therapeutics, LLC, is an early stage biotechnology company focused on using in vivo gene therapy technologies to treat hereditary disorders of unmet medical need. LEXEO is developing an in vivo gene therapy strategy to mitigate the high risk for osteoporosis in individuals with aldehyde dehydro- genase 2 (ALDH2) deficiency, a hereditary disorder affecting 8% of the world population ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health